Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16936331rdf:typepubmed:Citationlld:pubmed
pubmed-article:16936331lifeskim:mentionsumls-concept:C0024337lld:lifeskim
pubmed-article:16936331lifeskim:mentionsumls-concept:C0036421lld:lifeskim
pubmed-article:16936331lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:16936331lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:16936331lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:16936331pubmed:issue3lld:pubmed
pubmed-article:16936331pubmed:dateCreated2007-2-19lld:pubmed
pubmed-article:16936331pubmed:abstractTextAdvanced glycation endproducts (AGEs), including Nepsilon-(carboxymethyl)lysine-protein adducts (CML) are involved in micro/macrovascular changes and are co-localized with adhesion molecules in inflamed tissues. Serum levels of CML were investigated in systemic sclerosis (SSc) characterized by microvascular modifications and correlated with indices of micro/macrovascular damage.lld:pubmed
pubmed-article:16936331pubmed:languageenglld:pubmed
pubmed-article:16936331pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16936331pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16936331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16936331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16936331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16936331pubmed:statusMEDLINElld:pubmed
pubmed-article:16936331pubmed:monthMarlld:pubmed
pubmed-article:16936331pubmed:issn1462-0324lld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:BartoliFFlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:BasteCClld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:AbbateRRlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:CastellaniSSlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:De CaterinaRRlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:Del RossoAAlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:Matucci-Cerin...lld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:LiviRRlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:PignoneAAlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:PerfettoFFlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:GeneriniSSlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:ConfortiM LMLlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:GuiducciSSlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:MiniatiIIlld:pubmed
pubmed-article:16936331pubmed:authorpubmed-author:KaloudiOOlld:pubmed
pubmed-article:16936331pubmed:issnTypePrintlld:pubmed
pubmed-article:16936331pubmed:volume46lld:pubmed
pubmed-article:16936331pubmed:ownerNLMlld:pubmed
pubmed-article:16936331pubmed:authorsCompleteYlld:pubmed
pubmed-article:16936331pubmed:pagination412-6lld:pubmed
pubmed-article:16936331pubmed:dateRevised2007-9-6lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:meshHeadingpubmed-meshheading:16936331...lld:pubmed
pubmed-article:16936331pubmed:year2007lld:pubmed
pubmed-article:16936331pubmed:articleTitleCirculating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis.lld:pubmed
pubmed-article:16936331pubmed:affiliationDepartment of Medicine, Division of Rheumatology, University of Florence, Florence, Italy.lld:pubmed
pubmed-article:16936331pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16936331lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16936331lld:pubmed